Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 3/20 | 0.68 |
| ▸ | GPBAR1 | Q8TDU6 | 10/20 | 0.59 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.59 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.59 |
| ▸ | EFNA1 | P20827 | 1/20 | 0.59 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.59 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.59 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.59 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.59 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.59 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | ABCC4 | O15439 | 3/20 | 0.58 |
| ▸ | VDR | P11473 | 2/20 | 0.58 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.56 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1615267 | 0.97 | EPHA2 (0.72) | EPHA2GPBAR1AKR1B10AKR1B1EFNA1 | |
| Sulfuric Acid SCHEMBL2285700 | 0.96 | EPHA2 (0.67) | EPHA2GPBAR1AKR1B10AKR1B1EFNA1 | |
| Iodide SCHEMBL17786177 | 0.96 | EPHA2 (0.71) | EPHA2GPBAR1AKR1B10AKR1B1EFNA1 | |
| Iodide SCHEMBL17786176 | 0.96 | EPHA2 (0.71) | EPHA2GPBAR1AKR1B10AKR1B1EFNA1 | |
| Iodide SCHEMBL17786159 | 0.93 | EPHA2 (0.71) | EPHA2GPBAR1AKR1B10AKR1B1EFNA1 | |
| Iodide SCHEMBL17786157 | 0.93 | EPHA2 (0.71) | EPHA2GPBAR1AKR1B10AKR1B1EFNA1 | |
| SCHEMBL55596 | 0.92 | EPHA2 (0.68) | EPHA2GPBAR1AKR1B10AKR1B1EFNA1 | |
| Sulfuric Acid SCHEMBL10535471 | 0.92 | EPHA2 (0.68) | EPHA2GPBAR1AKR1B10AKR1B1EFNA1 | |
| Iodide SCHEMBL17786149 | 0.92 | EPHA2 (0.70) | EPHA2GPBAR1AKR1B10AKR1B1EFNA1 | |
| Iodide SCHEMBL17786150 | 0.92 | EPHA2 (0.70) | EPHA2GPBAR1AKR1B10AKR1B1EFNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2610315-B1 | Methine-substituted cyanine dye compounds | LIFE TECHNOLOGIES CORP (US) | 2016-08-31 | — | — | EP | disclosed |
| WO-2015058025-A1 | VAULTS ENGINEERED FOR HYDROPHOBIC DRUG DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-04-23 | — | — | WO | disclosed |
| EP-2037904-B1 | BASIC ACETOPHENONES AS INHIBITORS OF NO-SYNTHASES | UNIV KIEL CHRISTIAN ALBRECHTS (DE) | 2012-09-19 | — | — | EP | disclosed |
| EP-1262490-B1 | GPib-LIPID BOND CONSTRUCT AND USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2007-10-03 | — | — | EP | disclosed |
| US-6926884-B2 | GPIb-lipid bond construct and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2005-08-09 | — | — | US | disclosed |
| EP-1257560-A4 | BCL-2-LIKE POLYNUCLEOTIDES, POLYPEPTIDES, AND ANTIBODIES | HUMAN GENOME SCIENCES INC (US) | 2003-10-01 | — | — | EP | disclosed |
| US-20030113262-A1 | Gpib-lipid bond construct and use thereof | IKEDA, YASUO (JP) | 2003-06-19 | — | — | US | disclosed |
| US-20020183369-A1 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | DU BOIS DAISY JOE (US) | 2002-12-05 | — | — | US | disclosed |
| EP-1262490-A1 | GPib-LIPID BOND CONSTRUCT AND USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2002-12-04 | — | — | EP | disclosed |
| EP-1257560-A1 | BCL-2-LIKE POLYNUCLEOTIDES, POLYPEPTIDES, AND ANTIBODIES | HUMAN GENOME SCIENCES, INC. (US) | 2002-11-20 | — | — | EP | disclosed |
| WO-2000020449-A9 | MODIFIED TGF-β SUPERFAMILY PROTEINS | STRYKER CORP (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-2001057060-A1 | BCL-2-LIKE POLYNUCLEOTIDES, POLYPEPTIDES, AND ANTIBODIES | HUMAN GENOME SCIENCES, INC. (US) | 2001-08-09 | — | — | WO | disclosed |
| EP-1117804-A2 | CHIMAERIC PROTEINS BETWEEN MEMBERS OF TGF-BETA SUPERFAMILY | STRYKER CORPORATION (US) | 2001-07-25 | — | — | EP | disclosed |
| EP-1117805-A2 | MODIFIED TGF-BETA SUPERFAMILY PROTEINS | STRYKER CORPORATION (a Michigan corporation) (US) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000020607-A9 | CHIMAERIC PROTEINS BETWEEN MEMBERS OF TGF-BETA SUPERFAMILY | STRYKER CORP (US) | 2001-03-29 | — | — | WO | disclosed |
| WO-2000033075-A1 | METHOD AND APPARATUS FOR THE SEPARATION OF COMPONENTS FROM A BIOLOGICAL MATERIAL | PROTEOSYS AG (DE) | 2000-06-08 | — | — | WO | disclosed |
| WO-2000020449-A2 | MODIFIED TGF-β SUPERFAMILY PROTEINS | STRYKER CORPORATION (US) | 2000-04-13 | — | — | WO | disclosed |
| WO-2000020607-A2 | CHIMAERIC PROTEINS BETWEEN MEMBERS OF TGF-BETA SUPERFAMILY | STRYKER CORPORATION (US) | 2000-04-13 | — | — | WO | disclosed |
| WO-1989003885-A1 | METHOD OF REMOVING ENDOTOXIN CONTAMINANTS | CENTOCOR, INC. (US) | 1989-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183369-A1 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | PYGL, PYGM, PYGB | EPHA2 3829/4885GPBAR1 839/4885AKR1B10 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.